Indications
Each indication opens its study.
Oncology
Stage of development
-
PNB-291
Brain CancerPan-CCK blocker
- Molecule
- PNB-291
- Indication
- Brain Cancer
- Biological action
- Pan-CCK blocker
- Status
- IND ready
- Target and mechanism
- Non-selective (pan) CCK antagonist blocking both gastrin and cholecystokinin signalling. A more potent sister molecule of PNB-091.
- Key findings
Close to 90% inhibition in the MAC16 allograft model at 30 mg/kg.
Its sister molecule PNB-091 reduced U87 human brain-tumour volume in nude mice to about a third of control after 30 days, dose-dependently.
- Development
Two-step synthesis, purity above 99.7%. A second fluorine atom blocks metabolism to improve oral bioavailability. ICH toxicology studies are to be launched.
- Intellectual property
- Patents filed in the US, Europe and rest of world; USPTO patent issued 28 December 2014.
Interested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
